Literature DB >> 24253934

New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.

Zoe Mariño1, Florian van Bömmel, Xavier Forns, Thomas Berg.   

Abstract

Entities:  

Keywords:  ANTIVIRAL THERAPY; HCV

Mesh：

Substances：

Year:  2013        PMID： 24253934     DOI： 10.1136/gutjnl-2013-305771

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

Review 1.  Management of HCV in cirrhosis-a rapidly evolving landscape.

Authors:  Suraj A Sharma; Jordan J Feld
Journal:  Curr Gastroenterol Rep       Date:  2015-05

Review 2.  New approaches in the treatment of hepatitis C.

Authors:  Rocío González-Grande; Miguel Jiménez-Pérez; Carolina González Arjona; José Mostazo Torres
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 3.  A mini-review on Sofosbuvir and Daclatasvir treatment in COVID-19.

Authors:  Mehdi Shabani; Bahar Sadegh Ehdaei; Farshid Fathi; Razieh Dowran
Journal:  New Microbes New Infect       Date:  2021-05-07

Review 4.  Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection.

Authors:  Hye Jin Yang; Ju Yeon Ryoo; Bong Kyu Yoo
Journal:  Int J Clin Pharm       Date:  2015-06-06

Review 5.  Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.

Authors:  Sarah L Greig
Journal:  Drugs       Date:  2016-10       Impact factor: 11.431

Review 6.  Sofosbuvir: a review of its use in patients with chronic hepatitis C.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-07       Impact factor: 11.431

Review 7.  Sofosbuvir: a novel oral agent for chronic hepatitis C.

Authors:  Evangelos Cholongitas; George V Papatheodoridis
Journal:  Ann Gastroenterol       Date:  2014

8.  Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?

Authors:  Babak Sayad; Mahsa Sobhani; Reza Khodarahmi
Journal:  Arch Med Res       Date:  2020-04-29       Impact factor: 2.235

Review 9.  Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24.

Authors:  Helena H Borba; Astrid Wiens; Laiza M Steimbach; Cassio M Perlin; Fernanda S Tonin; Maria L A Pedroso; Fernando Fernandez-Llimos; Roberto Pontarolo
Journal:  Eur J Clin Pharmacol       Date:  2016-10-19       Impact factor: 3.064

10.  Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.

Authors:  Ye Wang; Hui-Ying Rao; Xing-Wang Xie; Lai Wei
Journal:  Chin Med J (Engl)       Date:  2015-10-05       Impact factor: 2.628
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.